Drug intelligence / Profile preview

NG33

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NG33 is a monoclonal antibody developed to target Human Epidermal Growth Factor Receptor 3 (HER3), a receptor tyrosine kinase implicated in cancer. It functions by degrading HER3, reducing downstream signaling pathways, and inhibiting the growth of cultured cancer cells. Preclinical studies have shown NG33 to be a potent inhibitor of pancreatic cancer cells in animal models, suggesting its potential to intercept autocrine and stroma-tumor interactions, similar to anti-EGFR antibodies used in colorectal cancer.

Targets

ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on NG33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NG33.

Explore the full profile